Delta Phenomics BV

Delta Phenomics is a preclinical contract research organisation (CRO) specialized in the analysis of animal behavior. We combine a longstanding expertise in behavioral pharmacology and neuroscience with a unique automated behavioral testing and data analysis platform. Our key expertise is in-vivo compound screening for drug discovery and safety pharmacology studies and behavioral phenotyping of genetically-modified rodents. We offer a number of unique animal models in neuroscience and oncology.
Name of the contact person: 
Dr. Helen Pothuizen
Street / City / Postal code: 
Nistelrooisebaan 3, 5374 RE Schaijk
the Netherlands
Trade register number: 
9174402 (Arnhem, the Netherlands)
Number of employees: 
The incentive aims to create a collaboration between the following two regions: 
Province of Noord-Brabant, the Netherlands
Denmark (any region)
Name of the organisation: 
Contera Pharma ApS
Name of the contact person: 
Dr. Mikael Thomsen
Street / City / Postal code: 
Kvaesthusgade 5C, 4th floor, DK–1251 Copenhagen
Phone (direct line): 
+45 23276134
Type of organisation: 
Is the organization mentioned in the IN2LifeSciences’ online catalogue?: 
Please describe the activities to be funded with the incentive: 
Conventional anxiety tests in rodents have limited validity and translational power. This is problematic in times when most of the preclinical tested drugs fail to show efficacy in the clinic. As a solution, Delta Phenomics has co-developed an instrumented home cage (the PhenoTyper), which allows the continuous automated monitoring of rodent behavior (including anxiety) in a relatively stress-free environment. Stress is a confounding factor in behavioral testing. To persuade others of the added value of our approach and to achieve a wider implementation in drug discovery, pharmacological validation is needed. We will use the incentive to test known anxiolytic compounds in both our novel anxiety test in the PhenoTyper, as well as a conventional test. The compounds are provided by Contera Pharma, which has a strong interest in testing their synergistic drug combination for anxiolytic effects in rodents. A future aim could be to collaborate also on animal models for Parkinson’s disease.
Do the proposed activities meet the eligibility criteria listed in the guidelines?: 
These activities support SME in : 
Access to market
Has the company recently worked with any of the organization(s) with which contact will be established?: 
Phone (direct line): 
+31 85 773 1433
Unique id: 
Are you an SME under the European SME definitions? :